Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs. Read More
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals has a market
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company’s continued growth and diversification.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a market
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals has a market
